C4 Therapeutics (CCCC) Shares Outstanding (2019 - 2026)

C4 Therapeutics' Shares Outstanding (Entity) history runs 8 years deep, the most recent figure standing at $104.0 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 46.55% year-over-year to $104.0 million; the TTM figure through Mar 2026 stood at $104.0 million (up 46.55% YoY), while the FY2025 annual figure was $96.9 million, up 37.22% from the prior year.
• Shares Outstanding (Entity) for Q1 2026 stood at $104.0 million, up from $96.9 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $104.0 million in Q1 2026, with the low at $48.8 million in Q1 2022.
• The 5-year median for Shares Outstanding (Entity) is $68.8 million (2024), against an average of $64.0 million.
• The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Entity) grew 0.38% in 2023, then soared 46.55% in 2026.
• C4 Therapeutics' Shares Outstanding (Entity) stood at $49.0 million in 2022, then climbed by 1.38% to $49.6 million in 2023, then surged by 42.27% to $70.6 million in 2024, then surged by 37.22% to $96.9 million in 2025, then advanced by 7.35% to $104.0 million in 2026.
• Business Quant data shows CCCC's Shares Outstanding (Entity) at $104.0 million in Q1 2026, $96.9 million in Q4 2025, and $74.2 million in Q3 2025.